| Range: | 0.079-7.83 | Vol Avg: | 21792562 | Last Div: | 0 | Changes: | 0 |
| Beta: | 2.12 | Cap: | 0.01B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Mon Mar 28 2022 | Empoloyees: | 7 | ||
| CUSIP: | 20678X106 | CIK: | 0001896212 | ISIN: | US20678X1063 | Country: | US |
| CEO: | Dr. David Joszef Tapolczay | Website: | https://www.conduitpharma.com | ||||
CDT 0.09 Stock Price Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc. operates as a clinical stage specialty biopharmaceutical company that provides unmet medical needs in the areas of autoimmune disease and idiopathic male infertility. It's pipeline includes AZD1656 for the treatment of hashimoto's thyroiditis, renal transplant, uveitis, and preterm labor; and AZD5904 for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow